News & Updates

Continuous dopamine D2 receptor blockade does not appear to increase the risk of breakthrough psychosis in patients with first-episode schizophrenia, as shown in a study.

Treatment with inebilizumab significantly improved generalized myasthenia gravis (gMG) symptoms, as shown by a greater reduction in MG-Activities of Daily Living (MG-ADL) scores, among patients who were acetylcholine receptor antibody-positive (AChR-Ab+) or muscle-specific kinase antibody-positive (MuSK-Ab+), according to the phase III MINT* trial presented at AAN 2025.

A wrist-worn wearable that harnesses artificial intelligence (AI) for noninvasive modulation of the nervous system appears beneficial in patients with essential tremor, enabling them to regain greater control over their upper limb movements for everyday activities.

Atrial fibrillation (AF) carries a heightened risk of dementia, especially for those under 70 years of age, according to a European population-based study said to be the largest to date.